What to Know About GLP-1 Medications and Weight Management Programs
Learn how Eden connects patients to licensed providers to explore GLP-1 medications as part of medical weight management programs.
Discover how sublingual semaglutide is designed to work, why some patients may prefer it over injections, and how it compares to oral and injectable GLP-1s.
Sublingual semaglutide refers to a compounded GLP-1 receptor agonist formulation designed to dissolve under the tongue, allowing absorption through the oral mucosa. This route may bypass gastrointestinal breakdown and first-pass liver metabolism, which may allow for more direct absorption compared to oral tablets.
This formulation may be suitable for individuals seeking alternatives to injections or those who experience difficulty with oral tablets.
Learn more about Eden’s GLP-1 therapy offerings, available through licensed healthcare providers.
Sublingual semaglutide is designed to be placed under the tongue, where it may be absorbed through the oral mucosa. Semaglutide, the active compound in this formulation, is believed to act similarly to other GLP-1 receptor agonists by:
The mucoadhesive base used in some sublingual formulations is intended to prolong contact with the mucosal surface, which may help support absorption. However, there are currently no published clinical studies directly comparing the pharmacokinetics or outcomes of compounded sublingual semaglutide to FDA-approved oral or injectable formulations.
Sublingual semaglutide is administered without needles and may be a discreet option for individuals seeking alternatives to injections. Some formulations do not require refrigeration or injection-related training.
Its ease of use may support consistent use, particularly for individuals who prefer non-injectable options. However, clinical adherence and outcome data for compounded sublingual semaglutide are limited.
Sublingual delivery bypasses the digestive tract, which may influence how the drug is absorbed. However, data comparing fluctuations in drug levels or side effect profiles between sublingual and other delivery methods are currently lacking.
Compounded sublingual semaglutide is available in a variety of strengths, such as 3 mg, and is dosed once daily under the tongue. A licensed healthcare provider will determine the starting dose and make adjustments based on your individual response and any side effects.
Because this formulation has not been reviewed or approved by the FDA, dosing practices are based on clinical judgment and patient-reported outcomes.
If you're interested in exploring this option, you can consult with a licensed healthcare provider through Eden to determine whether this therapy may be suitable for your health goals.
Start your sublingual semaglutide consultation with licensed healthcare providers on the Eden platform.
While formal clinical trials have not evaluated the safety of compounded sublingual semaglutide, patients using this formulation have reported a range of potential side effects, including:
These effects are similar to those seen with other GLP-1 receptor agonists but may vary based on individual tolerance and route of administration.
To support tolerability, licensed healthcare providers may recommend the following general strategies:
Always follow the guidance of your licensed healthcare provider and report any persistent or concerning side effects promptly.
Always follow the specific storage and dosing instructions provided by your pharmacy and healthcare provider.
Compounded sublingual semaglutide provides a needle-free option for delivering semaglutide, a GLP-1 receptor agonist used in managing certain metabolic health goals. While this formulation has not been reviewed or approved by the FDA, it is available through licensed compounding pharmacies and prescribed under the supervision of a licensed healthcare provider.
Some patients prefer sublingual delivery due to its convenience or difficulty with injections. However, there are currently no clinical studies comparing the safety, absorption, or effectiveness of compounded sublingual semaglutide to FDA-approved injectable or oral GLP-1 formulations.
Learn more about Eden’s personalized GLP-1 therapy options
This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or modifying any medication or treatment plan.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
No. Semaglutide is FDA-approved in injectable (Ozempic®, Wegovy®) and oral (Rybelsus®) forms. However, sublingual semaglutide is a compounded formulation and has not been reviewed or approved by the FDA.
Sublingual semaglutide may be considered by individuals who prefer to avoid injections or who have difficulty tolerating oral tablets. A licensed healthcare provider can help determine whether this option is appropriate for your needs.
Sublingual administration is designed to bypass the digestive system, which may influence how quickly it is absorbed. However, there are no published clinical trials directly comparing the onset of action between compounded sublingual and oral tablet forms of semaglutide.
Some individuals report mild irritation under the tongue or altered taste. Gastrointestinal symptoms such as nausea may still occur, though individual tolerance varies. Formal safety studies on the sublingual formulation have not been conducted.
Licensed healthcare providers may recommend waiting a few minutes after the tablet dissolves to support absorption through the oral mucosa. Follow the specific instructions provided with your prescription.